Steatohepatitis/Metabolic Liver Disease News

The average number of deaths from excessive alcohol use increased by 29.3% from 2016 to 2021, with an age-standardized rise in death rate from 38.1 to 47.6 per 100,000 population, according to data in Morbidity and Mortality Weekly Report.

Madrigal Pharmaceutical’s Rezdiffra received accelerated FDA approval for the treatment of patients with metabolic dysfunction-associated steatohepatitis with moderate-to-advanced fibrosis, according to a company release.

Sodium-glucose cotransporter 2 inhibitors were associated with a higher likelihood of disease regression among patients with concomitant metabolic dysfunction-associated steatotic liver disease and type 2 diabetes, data showed.

Non-alcoholic fatty liver disease is an independent risk factor for osteoarthritis, according to data published in Arthritis Research & Therapy.

DENVER — A low weekly dose of semaglutide can safely minimize what used to be called nonalcoholic fatty liver disease in people with HIV, a first-of-its-kind study found.

Researchers have estimated that annual costs associated with alcohol-associated liver disease will climb from $31 billion in 2022 to $66 billion in 2040 — a 118% increase — with costs among women accounting for 43% of the total expenditure.

Resmetirom 80 mg and 100 mg outperformed placebo in disease resolution and improvement in liver fibrosis among patients with metabolic dysfunction-associated steatohepatitis, according to 52-week results from the MAESTRO-NASH trial.

Topline findings from a phase 2 trial showed that survodutide achieved “statistically significant improvement” for metabolic dysfunction-associated steatohepatitis and liver fibrosis in 83% of patients, Boehringer Ingelheim announced.

Around 17% of patients with metabolic dysfunction-associated steatotic liver disease have or will be diagnosed with alcohol-related disease, which research shows is associated with a threefold higher rate of developing cirrhosis or cancer.

Increased intake of dietary niacin may reduce the risk for all-cause mortality but not cardiovascular disease-related mortality among patients with metabolic dysfunction-associated steatotic liver disease, data showed.